|
1
|
Li Destri G, Giarrizzo A, Bellavia N,
Milazzotto R, Frattalone ME, Scilletta B and Di Cataldo A:
Synchronous double cancers of the colon and the pancreas: a case
report. Eur Rev Med Pharmacol Sci. 18(Suppl 2): 28–31.
2014.PubMed/NCBI
|
|
2
|
Li J, Yen C, Liaw D, Podsypanina K, Bose
S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al:
PTEN, a putative protein tyrosine phosphatase gene mutated in human
brain, breast, and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Costa HA, Leitner MG, Sos ML, Mavrantoni
A, Rychkova A, Johnson JR, Newton BW, Yee MC, De La Vega FM, Ford
JM, Krogan NJ, Shokat KM, Oliver D, Halaszovich CR and Bustamante
CD: Discovery and functional characterization of a neomorphic PTEN
mutation. Proc Natl Acad Sci USA. 112:13976–13981. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maccioni F, Martinelli M, Al Ansari N,
Kagarmanova A, De Marco V, Zippi M and Marini M: Magnetic resonance
cholangiography: past, present and future: a review. Eur Rev Med
Pharmacol Sci. 14:721–725. 2010.PubMed/NCBI
|
|
5
|
Squadroni M and Fazio N: Chemotherapy in
pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci. 14:386–394.
2010.PubMed/NCBI
|
|
6
|
Hermanek P and Sobin LH: International
Union Against Cancer (UICC): TNM Classification of Malignant
Tumours (4th). New York, NY: Springer. 712731992.
|
|
7
|
Depowski PL, Rosenthal SI and Ross JS:
Loss of expression of the PTEN gene protein product is associated
with poor outcome in breast cancer. Mod Pathol. 14:672–676. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang J, Li Z, Yu C, Chen M, Tian S and
Sun C: MiR-1181 inhibits stem cell-like phenotypes and suppresses
SOX2 and STAT3 in human pancreatic cancer. Cancer Lett. 356(2 Pt
B): 962–970. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morran DC, Wu J, Jamieson NB, Mrowinska A,
Kalna G, Karim SA, Au AY, Scarlett CJ, Chang DK, Pajak MZ, et al:
Australian Pancreatic Cancer Genome Initiative (APGI): Targeting
mTOR dependency in pancreatic cancer. Gut. 63:1481–1489. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Humphris JL, Johns AL, Simpson SH, Cowley
MJ, Pajic M, Chang DK, Nagrial AM, Chin VT, Chantrill LA, Pinese M,
et al: Australian Pancreatic Cancer Genome Initiative: Clinical and
pathologic features of familial pancreatic cancer. Cancer.
120:3669–3675. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vazquez F, Ramaswamy S, Nakamura N and
Sellers WR: Phosphorylation of the PTEN tail regulates protein
stability and function. Mol Cell Biol. 20:5010–5018. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamaguchi K, Okusaka T, Shimizu K, Furuse
J, Ito Y, Hanada K and Shimosegawa T: Committee for revision of
clinical guidelines for pancreatic cancer of Japan Pancreas
Society: EBM-based Clinical Guidelines for Pancreatic Cancer (2013)
issued by the Japan Pancreas Society: A synopsis. Jpn J Clin Oncol.
44:883–888. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhan HX, Xu JW, Wu D, Zhang TP and Hu SY:
Pancreatic cancer stem cells: new insight into a stubborn disease.
Cancer Lett. 357:429–437. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Limani P, Samaras P, Lesurtel M, Graf R,
DeOliveira ML, Petrowsky H and Clavien PA: Pancreatic cancer - a
curable disease. Praxis (Bern 1994). 104:453–460. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Grant RC, Selander I, Connor AA,
Selvarajah S, Borgida A, Briollais L, Petersen GM, Lerner-Ellis J,
Holter S and Gallinger S: Prevalence of germline mutations in
cancer predisposition genes in patients with pancreatic cancer.
Gastroenterology. 148:556–564. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang M, Tang SN, Upadhyay G, Marsh JL,
Jackman CP, Srivastava RK and Shankar S: Rottlerin suppresses
growth of human pancreatic tumors in nude mice, and pancreatic
cancer cells isolated from Kras(G12D) mice. Cancer Lett. 353:32–40.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stewart DJ, Nunez MI, Jelinek J, Hong D,
Gupta S, Aldaz M, Issa JP, Kurzrock R and Wistuba II: Impact of
decitabine on immunohistochemistry expression of the putative tumor
suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor
samples. Clin Epigenetics. 6:132014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakanishi A, Kitagishi Y, Ogura Y and
Matsuda S: The tumor suppressor PTEN interacts with p53 in
hereditary cancer (Review). Int J Oncol. 44:1813–1819.
2014.PubMed/NCBI
|
|
19
|
Suda T, Oba H, Takei H, Kurosumi M,
Hayashi S and Yamaguchi Y: ER-activating ability of breast cancer
stromal fibroblasts is regulated independently of alteration of
TP53 and PTEN tumor suppressor genes. Biochem Biophys Res Commun.
428:259–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim SJ, Jung HJ and Lim CJ: Reactive
oxygen species-dependent down-regulation of tumor suppressor genes
PTEN, USP28, DRAM, TIGAR, and CYLD under oxidative stress. Biochem
Genet. 51:901–915. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lang Y, Xu S, Ma J, Wu J, Jin S, Cao S and
Yu Y: MicroRNA-429 induces tumorigenesis of human non-small cell
lung cancer cells and targets multiple tumor suppressor genes.
Biochem Biophys Res Commun. 450:154–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang H, Chen H, Qiu Z, et al: Preliminary
screening of drug resistance-related genes downstream of STAT3 in
human pancreatic cancer cell. Chin J Gen Surg. 20:925–930.
2011.
|
|
23
|
Gautam A, Li ZR and Bepler G: RRM1-induced
metastasis suppression through PTEN-regulated pathways. Oncogene.
22:2135–2142. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hayashi Y, Kajikawa M, Matsumoto T and
Okada N: Mechanism by which a LINE protein recognizes its 3′ tail
RNA. Nucleic Acids Res. 42:10605–10617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Camenares D, Dulebohn DP, Svetlanov A and
Karzai AW: Active and accurate trans-translation requires distinct
determinants in the C-terminal tail of SmpB protein and the
mRNA-like domain of transfer messenger RNA (tmRNA). J Biol Chem.
288:30527–30542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vallazza B, Petri S, Poleganov MA, Eberle
F, Kuhn AN and Sahin U: Recombinant messenger RNA technology and
its application in cancer immunotherapy, transcript replacement
therapies, pluripotent stem cell induction, and beyond. Wiley
Interdiscip Rev RNA. 6:471–499. 2015.(In Chinese). View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yi X, Jiang T, Zhai H, et al: Experimental
study of lentiviral vector intermediate RNAi target on inhibiting
the expression of pancreatic cancer cell survivin and its effect in
inducing cell apoptosis. Chin J Gen Surg. 19:227–233. 2010.(In
Chinese).
|
|
28
|
Xiang C, Zheng Y and Shi Z: The influence
of the expression change of microRNA-10b on biological behavior of
pancreatic cancer cell. Chin J Gen Surg. 21:1091–1092. 2012.
|
